,Abstract,Outcome 1,Outcome 2,Outcome 3,Outcome 4,Outcome 5,Outcome 6
0,"The virological clearance rate of throat swabs, sputum, or lower",,,,,,
1,Length of,,,,,,
2,Compliance,,,,,,
3,nan,,,,,,
4,Symptomatic non-COVID viral infection,,,,,,
5,nan,,,,,,
6,Positive SARS-CoV-2 rt-PCR test,Positive SARS-CoV-2:PHYSIOLOGICAL-CLINICAL,,,,,
7,Number of asymptomatic cases,,,,,,
8,28-day mortality Duration of mechanical,,,,,,
9,Acute respiratory illness Absenteeism Lower,,,,,,
10,28-day mortality Duration of mechanical ventilation,,,,,,
11,Geometric mean fold rise (GMFR) in IgG,,,,,,
12,Safety indexes of adverse,,,,,,
13,nan,,,,,,
14,Traditional Chinese,,,,,,
15,body temperature,,,,,,
16,Hepatorenal function Heart rate Blood,,,,,,
17,nan,,,,,,
18,nan,,,,,,
19,Vital signs,,,,,,
20,Clinical manifestations and severity of,,,,,,
21,nan,,,,,,
22,self-assessment scale moxa related Questionaire NCP related,,,,,,
23,New coronavirus infection before,,,,,,
24,Incidence of fever Incidence of cough Incidence,,,,,,
25,nan,,,,,,
26,nan,,,,,,
27,nan,,,,,,
28,nan,,,,,,
29,nan,,,,,,
30,adverse reactions 28 days post injection SAE anti-S,28 days post injection SAE anti-S:RESOURCE-USE,,,,,
31,Time-to-first clinical event,,,,,,
32,nan,,,,,,
33,SARS-CoV-2 seroconversion Occurrence,SARS-CoV-2 seroconversion:PHYSIOLOGICAL-CLINICAL,,,,,
34,Rate of participant-reported adverse events Incidence rates of,,,,,,
35,nan,,,,,,
36,Adverse events Adverse events,Adverse events:ADVERSE-EFFECTS,,,,,
37,Evaluation of,Evaluation of:LIFE-IMPACT,,,,,
38,COVID-19 incidence by 12 months Severe COVID-19,months Severe:PHYSIOLOGICAL-CLINICAL,,,,,
39,"Assess the safety, tolerability and reactogenicity profile of","safety, tolerability and:LIFE-IMPACT",reactogenicity profile of:PHYSIOLOGICAL-CLINICAL,,,,
40,The cumulative incidence of documented SARS-CoV-2 infection,documented SARS-CoV-2:PHYSIOLOGICAL-CLINICAL,,,,,
41,COVID-19 disease symptoms severity Adverse effects,symptoms severity Adverse effects:ADVERSE-EFFECTS,,,,,
42,nan,,,,,,
43,Number,Number:PHYSIOLOGICAL-CLINICAL,,,,,
44,Adverse events Symptomatic COVID-19 disease Seropositivity Days of,Symptomatic COVID-19 disease Seropositivity Days of:PHYSIOLOGICAL-CLINICAL,,,,,
45,Number of Covid-19 positive participants,positive participants:LIFE-IMPACT,,,,,
46,Incidence of confirmed SARS-CoV-2 detection Incidence of possible COVID-19,,,,,,
47,Mean oxygen flow Time,flow:PHYSIOLOGICAL-CLINICAL,,,,,
48,Positive serology at day 28 Symptoms of COVID-19,,,,,,
49,nan,,,,,,
50,Severity of disease in confirmed,,,,,,
51,nan,,,,,,
52,Antibody-screening,,,,,,
53,nan,,,,,,
54,SARS-CoV-2 Antibodies Incidence of COVID-19 infection bacTRL-Spike in stool post-vaccination Seroconversion of circulating anti-Spike IgG antibodies & stability of,,,,,,
55,Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19 Prevention Study: Measure the tolerability of NORS,,,,,,
56,Severity of Disease,,,,,,
57,absence,,,,,,
58,Reducing clinical episodes due to,,,,,,
59,Effect of basic,,,,,,
60,Viral,,,,,,
61,Comparison,,,,,,
62,Occurrence,,,,,,
63,nan,,,,,,
64,Salivary cytokine,,,,,,
65,nan,,,,,,
66,COVID19-related disease,,,,,,
67,Percent of agreement,of agreement:LIFE-IMPACT,,,,,
68,ICU transfer Oxygen,transfer:LIFE-IMPACT,,,,,
69,nan,,,,,,
70,Rapid Assessment of Physical Activity Global Rating of Change,,,,,,
71,o 28-day mortality o Need for ICU,,,,,,
72,Incidence of symptomatic SARS-CoV-2 infections Symptom severity of COVID-19 Duration of,,,,,,
73,"COVID-19 symptom score, Integral","COVID-19 symptom score, Integral:PHYSIOLOGICAL-CLINICAL",,,,,
74,Effectiveness of the different media outlets,,,,,,
75,Adverse event reported Diagnosis of SARS-CoV-2 COVID-19 infection,,,,,,
76,"Mortality, gravity of COVID-19",,,,,,
77,1),,,,,,
78,Number,,,,,,
79,nan,,,,,,
80,nan,,,,,,
81,Number,,,,,,
82,Interleukin-6 level Lymphocyte count CRP (C-reactive protein) level PaO2 (partial pressure of oxygen) / FiO2,level PaO2 (partial:PHYSIOLOGICAL-CLINICAL,,,,,
83,nan,,,,,,
84,nan,,,,,,
85,nan,,,,,,
86,nan,,,,,,
87,nan,,,,,,
88,nan,,,,,,
89,nan,,,,,,
90,nan,,,,,,
91,nan,,,,,,
92,Conversion rate of,,,,,,
93,nan,,,,,,
94,nan,,,,,,
95,nan,,,,,,
96,nan,,,,,,
97,nan,,,,,,
98,nan,,,,,,
99,nan,,,,,,
100,nan,,,,,,
101,nan,,,,,,
102,nan,,,,,,
103,Length of,,,,,,
104,nan,,,,,,
105,nan,,,,,,
106,nan,,,,,,
107,nan,,,,,,
108,Rate of,,,,,,
109,nan,,,,,,
110,nan,,,,,,
111,nan,,,,,,
112,nan,,,,,,
113,nan,,,,,,
114,nan,,,,,,
115,Time to improvement in oxygenation,to improvement:PHYSIOLOGICAL-CLINICAL,,,,,
116,Change in National Early Warning Score,,,,,,
117,RT-PCR results,,,,,,
118,All cause mortality,,,,,,
119,Percentage,,,,,,
120,Change,,,,,,
121,body,,,,,,
122,Viral,,,,,,
123,Mortality,,,,,,
124,Number of patient,,,,,,
125,Not provided,,,,,,
126,Rate,,,,,,
127,PaO2,,,,,,
128,28-Day,,,,,,
129,Examine the percentage of,,,,,,
130,Clinical status assessed according to the,Clinical status:PHYSIOLOGICAL-CLINICAL,,,,,
131,Proportion of Participants With Treatment,,,,,,
132,Time to,,,,,,
133,Proportion of Participants With Treatment Emergent Adverse Events,,,,,,
134,TNF alpha Multi-system organ failure,,,,,,
135,Proportion of patients in each classification of,,,,,,
136,nan,,,,,,
137,The degree of remission of symptoms,,,,,,
138,nan,,,,,,
139,All cause mortality,,,,,,
140,Clinical status Time to Hospital Discharge OR NEWS2 (National,,,,,,
141,Time to CoVID-19 RT-PCR negative in upper,,,,,,
142,Clinical remission rate Dynamic changes of oxygenation index Time,Clinical:PHYSIOLOGICAL-CLINICAL,,,,,
143,"absolute lymphocyte counts serum level of CRP, PCT and IL-6 SOFA score all",lymphocyte counts:PHYSIOLOGICAL-CLINICAL,level:PHYSIOLOGICAL-CLINICAL,,,,
144,clinical cure incidence in 14 days the duration of virus change to,,,,,,
145,28 day mortality,,,,,,
146,Clinical status assessed by,,,,,,
147,Times of acute exacerbation Six-minute walk distance Dyspnea Scores Composite physiological index,,,,,,
148,Degree of dyspnea (Liker scale),,,,,,
149,28-day mortality Duration of mechanical ventilation Duration of hospitalization Proportion of patients with negative RT-PCR,patients with negative RT-PCR:PHYSIOLOGICAL-CLINICAL,,,,,
150,Improvement of Clinical symptoms,,,,,,
151,Time to recovery,,,,,,
152,All cause mortality Frequency of respiratory progression,,,,,,
153,The incidence,,,,,,
154,Rate of normal tempreture,,,,,,
155,Time of clinical remission Rate of no fever Rate of no cough Rate of no dyspnea Rate of,Rate:PHYSIOLOGICAL-CLINICAL,of:PHYSIOLOGICAL-CLINICAL,,,,
156,Rate of,,,,,,
157,Rate of no fever,,,,,,
158,Incidence of Hospitalization,,,,,,
159,Change from baseline in alanine transaminase (ALT) Change from baseline in aspartate,,,,,,
160,Virus negative conversion rate Antipyretic rate Symptom relief time Finger,,,,,,
161,28-days mortality ICU length of stay Demand for,,,,,,
162,nan,,,,,,
163,Clinical status Time to Hospital Discharge OR NEWS2,,,,,,
164,Number of participants with treatment-related adverse events,treatment-related adverse:ADVERSE-EFFECTS,,,,,
165,"The virological clearance rate of throat swabs, sputum,","swabs,:PHYSIOLOGICAL-CLINICAL",,,,,
166,Side effects in the UC-MSCs,,,,,,
167,need of oro-tracheal,,,,,,
168,Time of virus,,,,,,
169,Time to recovery Rate,recovery Rate:PHYSIOLOGICAL-CLINICAL,,,,,
170,Complete fever time Cough relief time Virus negative time Incidence of severe or critical neocoronavirus pneumonia,or:PHYSIOLOGICAL-CLINICAL,,,,,
171,The difference of PaO2/FiO2 between two groups,,,,,,
172,Viral nucleic acid test negative conversion rate and days from positive to negative Duration of,,,,,,
173,Absorption,,,,,,
174,Time from patient enrollment to,patient:PHYSIOLOGICAL-CLINICAL,,,,,
175,Time to negative saliva Time,,,,,,
176,death Time to disease progression or death within 4 weeks blood viral nucleic acid dyspnea score blood cough scores,nucleic acid:PHYSIOLOGICAL-CLINICAL,,,,,
177,"the incidence of hypoxia,",,,,,,
178,mortality laboratory,,,,,,
179,"clinical status,",,,,,,
180,Secondary indicator( Length from the day of admission to the day returning to normal body,the day:PHYSIOLOGICAL-CLINICAL,to normal body:PHYSIOLOGICAL-CLINICAL,,,,
181,Secondary indicator (Total duration of disease Time needed for healing Incidence of adverse events Number of sequelae SF-36 Mental health scale ),indicator:PHYSIOLOGICAL-CLINICAL,,,,,
182,Secondary,,,,,,
183,Secondary indicator ( ICU stay duration Viral titers,,,,,,
184,ADR,,,,,,
185,Secondary indicator (Effective rate of TCM symptoms antipyretic time clearance time,(Effective:PHYSIOLOGICAL-CLINICAL,,,,,
186,Secondary indicator (Chest imaging 6-minute walking distance Pulmonary function EQ-5D,,,,,,
187,Secondary indicator (vital signs,(vital signs:PHYSIOLOGICAL-CLINICAL,,,,,
188,Secondary indicator ( Virus negative,,,,,,
189,Secondary indicator( Safty Blood biochemistry,Secondary indicator(:PHYSIOLOGICAL-CLINICAL,,,,,
190,"Others (liver and kidney function, muscle enzymes, myoglobin)",,,,,,
191,"Clearance rate and time of main symptoms (fever, fatigue, cough) immune indices",,,,,,
192,nan,,,,,,
193,Pneumonia symptoms oxygenation index Routine,,,,,,
194,Total duration of,,,,,,
195,"Length from the day of admission to the day returning to normal body temperature, from admission to two",,,,,,
196,Time of virus turning negative Severe conversion rate Inflammation,,,,,,
197,"Clinical symptoms (fever, weakness, gastrointestinal discomfort, etc.) remission and",,,,,,
198,nan,,,,,,
199,Tempreture PSI score,,,,,,
200,"Improvement of TCM syndromes Relief of clinical symptoms (fever, fatigue, gastrointestinal",syndromes Relief:PHYSIOLOGICAL-CLINICAL,,,,,
201,Progression rate of 2019-nCoV pneumonia Rate of severe,,,,,,
202,nan,,,,,,
203,time to temperature normal breath symptoms and measure hospitalization days,,,,,,
204,CT X-ray Arterial,,,,,,
205,nan,,,,,,
206,"6-minute walk test, 6MWT",6-minute walk:PHYSIOLOGICAL-CLINICAL,,,,,
207,Arterial Oxygen Saturation Critical,,,,,,
208,nan,,,,,,
209,nan,,,,,,
210,Time from admission to clinical remission: Improvement,clinical remission: Improvement:PHYSIOLOGICAL-CLINICAL,,,,,
211,Conversion rate of common and critical illness Nucleic,,,,,,
212,nan,,,,,,
213,Routine blood test Biochemical Indicators Blood gas analysis C-reactive,Biochemical Indicators:PHYSIOLOGICAL-CLINICAL,,,,,
214,nan,,,,,,
215,nan,,,,,,
216,Antipyretic time Pulmonary function mortality and,Pulmonary function mortality:MORTALITY,,,,,
217,Hospitalization day Ventilator utilization mortality,mortality:MORTALITY,,,,,
218,Rate of disisolation TCM symptom,Rate of:PHYSIOLOGICAL-CLINICAL,disisolation TCM symptom:PHYSIOLOGICAL-CLINICAL,,,,
219,nan,,,,,,
220,28-day prognosis 84-day prognosis Chest imaging SF-36,84-day prognosis Chest:PHYSIOLOGICAL-CLINICAL,,,,,
221,Hemodiafiltration Mechanical ventilation time Application of pulmonary surfactant Oxygen time (hours) ICU,time:PHYSIOLOGICAL-CLINICAL,Application of pulmonary surfactant:PHYSIOLOGICAL-CLINICAL,time (hours) ICU:RESOURCE-USE,,,
222,Time to improvement of Virus infection symptoms Length of,improvement of:PHYSIOLOGICAL-CLINICAL,,,,,
223,pulmonary CT chest,,,,,,
224,Body temperature 3CL Mpro of Coronavirus Routine,,,,,,
225,nan,,,,,,
226,The time from the,,,,,,
227,Liver function,,,,,,
228,nan,,,,,,
229,CRP HRV,,,,,,
230,Virus negative conversion rate Symptom relief time Antipyretic rate Finger oxygen improvement rate Disease progression rate Mortality rate Change curve of peripheral blood lymphocyte count Incidence of severe adverse reactions,,,,,,
231,nan,,,,,,
232,nan,,,,,,
233,nan,,,,,,
234,CT X-ray Arterial blood gas analysis Assisted breathing use time mortality Disease evolution hospitalization day Safety outcome index,,,,,,
235,incidence of mechanical ventilation by day14 Incidence,,,,,,
236,all,,,,,,
237,Length of stay,,,,,,
238,Viral nucleic acid turns,,,,,,
239,28-day all-cause mortality total length of hospitalization ICU admission,,,,,,
240,Improvement rate in,rate:PHYSIOLOGICAL-CLINICAL,,,,,
241,28-day,,,,,,
242,Time,,,,,,
243,Time,,,,,,
244,Clinical,,,,,,
245,the,,,,,,
246,nan,,,,,,
247,nan,,,,,,
248,Incidence,,,,,,
249,Disappearance,,,,,,
250,"6-minute walk test, 6MWT",,,,,,
251,nan,,,,,,
252,Modified,,,,,,
253,Pulmonary,,,,,,
254,nan,,,,,,
255,nan,,,,,,
256,nan,,,,,,
257,Arterial,,,,,,
258,Conversion,,,,,,
259,28-day,,,,,,
260,nan,,,,,,
261,Major,,,,,,
262,nan,,,,,,
263,Main clinical,,,,,,
264,1.The,,,,,,
265,novel,,,,,,
266,nan,,,,,,
267,Rate,,,,,,
268,nan,,,,,,
269,PHQ-9 Length of hospital stay Respiratory symptoms,PHQ-9:PHYSIOLOGICAL-CLINICAL,,,,,
270,nan,,,,,,
271,Self-rating,,,,,,
272,Conversion,,,,,,
273,Antifebrile,,,,,,
274,Antifebrile,,,,,,
275,All-cause,,,,,,
276,nan,,,,,,
277,nan,,,,,,
278,blood pressure heart rate immunoglobin level,blood:PHYSIOLOGICAL-CLINICAL,heart:PHYSIOLOGICAL-CLINICAL,,,,
279,cure rate All-cause mortality Severity rate,,,,,,
280,nan,,,,,,
281,"Day 7, 14, 21, 28 clinical status Time from study entry to",,,,,,
282,Time to 2019-nCoV RT-PCR negativity in upper,,,,,,
283,CRP IL-6,,,,,,
284,Trough and,,,,,,
285,Improvement of,,,,,,
286,COVID-19 RNA negative,,,,,,
287,nan,,,,,,
288,mortality Ventilator utilization Hospitalization day,,,,,,
289,Frequency of exacerbations of dyspnea Antipyretic,,,,,,
290,All cause,,,,,,
291,nan,,,,,,
292,nan,,,,,,
293,Clearance rate,,,,,,
294,1. 28-day clinical improvement time: the number of days from randomization to clinical improvement.Clinical,randomization:LIFE-IMPACT,clinical:PHYSIOLOGICAL-CLINICAL,,,,
295,nan,,,,,,
296,Physical activity,,,,,,
297,"Sputum suction amount Circulation indicators: blood pressure,",suction:PHYSIOLOGICAL-CLINICAL,"pressure,:PHYSIOLOGICAL-CLINICAL",,,,
298,Survival rate,,,,,,
299,nan,,,,,,
300,Within,Within:PHYSIOLOGICAL-CLINICAL,,,,,
301,The 7-point scale The rate of,,,,,,
302,"TTCR, Time to Clinical Recovery Pulmonary",,,,,,
303,routine blood test blood biochemical routine urine test Sepsis,routine urine:PHYSIOLOGICAL-CLINICAL,test:LIFE-IMPACT,,,,
304,nan,,,,,,
305,nan,,,,,,
306,nan,,,,,,
307,Chest imaging Refers to oxygen,,,,,,
308,Nucleic acid detection of pharyngeal test Leukocytes and lymphocytes in blood routine,,,,,,
309,7,,,,,,
310,novel coronavirus,,,,,,
311,Routine blood test C-reactive protein,,,,,,
312,nan,,,,,,
313,nan,,,,,,
314,6-minute walk test basic ADL IADL,walk test:LIFE-IMPACT,,,,,
315,Antipyretic time Pulmonary CT inflammatory absorption Time of nucleic,Pulmonary CT:PHYSIOLOGICAL-CLINICAL,,,,,
316,30-day all-cause mortality Normal time of respiratory,,,,,,
317,Time,,,,,,
318,"including AE,",,,,,,
319,nan,,,,,,
320,Conversion rate of severe type to general type Conversion rate of,,,,,,
321,Time for body temperature to,,,,,,
322,Time to defervescence Time to absence,to defervescence:PHYSIOLOGICAL-CLINICAL,,,,,
323,fever feeble novel coronavirus nucleic acid detection Lung CT,,,,,,
324,rate of composite advers outcomes,,,,,,
325,Duration of hospitalization proportion of mechanical ventilation use mortality,of hospitalization proportion of mechanical:RESOURCE-USE,,,,,
326,nan,,,,,,
327,Safety observation index,,,,,,
328,all-cause mortality of 28-days Transition time of,,,,,,
329,Proportion of subjects with 6-grades rating form at,with:PHYSIOLOGICAL-CLINICAL,,,,,
330,mortality on day 28 The rate of negative,mortality on day 28:MORTALITY,rate of:PHYSIOLOGICAL-CLINICAL,,,,
331,All-cause death Adverse events,All-cause death Adverse:MORTALITY,,,,,
332,Time,,,,,,
333,Mechanical ventilation time (days) Total,ventilation time (days):LIFE-IMPACT,,,,,
334,ICU stay period Incubation period IL-6,ICU stay period Incubation:RESOURCE-USE,,,,,
335,"TTCR, Time to",,,,,,
336,nan,,,,,,
337,Laboratory examination,,,,,,
338,Clinical remission rate and time novel coronavirus nucleic,and time:PHYSIOLOGICAL-CLINICAL,,,,,
339,Time to,Time:PHYSIOLOGICAL-CLINICAL,,,,,
340,Time for improvement of clinical,Time for improvement:PHYSIOLOGICAL-CLINICAL,,,,,
341,Treatment compliance To evaluate the,,,,,,
342,NEW Score Hospital Stay 30-day all-cause mortality Levels of Inflammatory Factors and Oxidative,,,,,,
343,body tempture lung CT scan clearance time of COVID-19 Oxygen saturation duration,,,,,,
344,nan,,,,,,
345,nan,,,,,,
346,the incidence of hypoxia the times of intubation 7-day mortality,,,,,,
347,SF-36 score,,,,,,
348,nan,,,,,,
349,Clinical improvement scores at Day 28 Mechanical ventilation time,,,,,,
350,The fading and obviously improving time of,,,,,,
351,Comparison of TCM symptom score,,,,,,
352,Clinical improvement scores at Day,,,,,,
353,Time to COVID-19 RNA convert negative Other symptoms relief,,,,,,
354,nan,,,,,,
355,nan,,,,,,
356,Immunological indexs Procalcitonin Coagulation routine,,,,,,
357,nan,,,,,,
358,Single symptom disappearance rate,disappearance rate:PHYSIOLOGICAL-CLINICAL,,,,,
359,Time and rate of coronavirus become negative Proportion,Time and rate of:PHYSIOLOGICAL-CLINICAL,become negative:LIFE-IMPACT,,,,
360,28-day mortality Hospitalization time ICU hospitalization Invasive mechanical,28-day mortality Hospitalization time:MORTALITY,,,,,
361,nan,,,,,,
362,Viral nucleic acid,nucleic acid:PHYSIOLOGICAL-CLINICAL,,,,,
363,nan,,,,,,
364,nan,,,,,,
365,pH Oxygenation index PaCO2,,,,,,
366,nan,,,,,,
367,Clinical,,,,,,
368,nan,,,,,,
369,Pneumonia symptoms oxygenation index,oxygenation index:PHYSIOLOGICAL-CLINICAL,,,,,
370,nan,,,,,,
371,C-reactive protein Detection,protein Detection:PHYSIOLOGICAL-CLINICAL,,,,,
372,Hospital stay Inflammatory factor,,,,,,
373,Haematological C-reactive protein Blood,protein Blood:PHYSIOLOGICAL-CLINICAL,,,,,
374,28 natural survival rate,,,,,,
375,nan,,,,,,
376,nan,,,,,,
377,"SOFA score, APACHE II score time of mechanical ventilation Complications",,,,,,
378,traditional Chinese medical syndrome scale TCM symptom integral TCM Constitution body temperature Serum antibody cellular immune factor,scale TCM:PHYSIOLOGICAL-CLINICAL,,,,,
379,Total hospital stay,Total hospital stay:RESOURCE-USE,,,,,
380,All cause mortality Frequency of exacerbation of dyspnea,All cause mortality:MORTALITY,,,,,
381,28-day mortality,,,,,,
382,nan,,,,,,
383,Lung function,,,,,,
384,The incidence of mild or common novel coronavirus pneumonia,The incidence of mild:PHYSIOLOGICAL-CLINICAL,,,,,
385,The incidence of mild or common novel coronavirus pneumonia progressing to severe Time for the main,incidence of:PHYSIOLOGICAL-CLINICAL,,,,,
386,"Clearance rate and time of main symptoms (fever, fatigue, cough) Disappearance rate of single symptom in",rate and:PHYSIOLOGICAL-CLINICAL,,,,,
387,The incidence rate of complication,incidence rate:PHYSIOLOGICAL-CLINICAL,,,,,
388,"CRP IL-6 TNF-alpha time of improvement of clinical symptoms (fever, cough)",,,,,,
389,nan,,,,,,
390,T cell recovery time Remission time of,T:PHYSIOLOGICAL-CLINICAL,,,,,
391,"Level of IL2, IL4, IL6, IL10, TNF-alpha and IFN-gama Routine blood test lymphocyte subsets","of IL2,:PHYSIOLOGICAL-CLINICAL",,,,,
392,Comparison of,,,,,,
393,nan,,,,,,
394,Inflammatory markers,,,,,,
395,Time to Clinical,Time:PHYSIOLOGICAL-CLINICAL,,,,,
396,nan,,,,,,
397,Proportion of severe cases Length,,,,,,
398,nan,,,,,,
399,Remission time of,time:PHYSIOLOGICAL-CLINICAL,,,,,
400,The fading and obviously improving time of clinical,obviously:LIFE-IMPACT,time of:PHYSIOLOGICAL-CLINICAL,,,,
401,ICU length of stay Chest CT Routine,stay:LIFE-IMPACT,CT Routine:LIFE-IMPACT,,,,
402,Remission time of fever,,,,,,
403,Time of improvement of clinical symptoms Remission,of improvement:PHYSIOLOGICAL-CLINICAL,,,,,
404,Time and rate of coronavirus become,coronavirus become:PHYSIOLOGICAL-CLINICAL,,,,,
405,Time and rate,,,,,,
406,Chest distress Fatigue Sleep quality,,,,,,
407,Time and rate,and:PHYSIOLOGICAL-CLINICAL,,,,,
408,Time and rate of coronavirus become negative Clearance,,,,,,
409,Lung function oxygenation index,index:PHYSIOLOGICAL-CLINICAL,,,,,
410,Evaluation,Evaluation:LIFE-IMPACT,,,,,
411,Blood count liver and,Blood count liver:PHYSIOLOGICAL-CLINICAL,,,,,
412,nan,,,,,,
413,nan,,,,,,
414,PHQ-9 A Coping,,,,,,
415,nan,,,,,,
416,Total,,,,,,
417,nan,,,,,,
418,Secondary symptom grading quantification table,,,,,,
419,nan,,,,,,
420,nan,,,,,,
421,Dyspnea evaluation,Dyspnea evaluation:PHYSIOLOGICAL-CLINICAL,,,,,
422,nan,,,,,,
423,nan,,,,,,
424,nan,,,,,,
425,Improving,Improving:PHYSIOLOGICAL-CLINICAL,,,,,
426,Recurrence rate of COVID-19,Recurrence rate of COVID-19:PHYSIOLOGICAL-CLINICAL,,,,,
427,WBC PBML,,,,,,
428,Causal mortality COVID-19 nucleic,Causal mortality COVID-19 nucleic:MORTALITY,,,,,
429,hepatic and,,,,,,
430,Differences in mean clinical,,,,,,
431,time till the SARS-CoV-2 clearance,,,,,,
432,Adverse events,events:PHYSIOLOGICAL-CLINICAL,,,,,
433,Progression,,,,,,
434,Duration of hospitalization Clinical outcome,Clinical outcome:PHYSIOLOGICAL-CLINICAL,,,,,
435,Duration of hospitalization Mortality,Duration of hospitalization Mortality:MORTALITY,,,,,
436,Duration of hospitalization,Duration:RESOURCE-USE,,,,,
437,nan,,,,,,
438,Hospitalization duration Lung,,,,,,
439,Duration of hospitalization Clinical outcome (cure or death),,,,,,
440,Requirement for mechanical ventilation Radiological changes Serious adverse events All-cause,for:PHYSIOLOGICAL-CLINICAL,mechanical:PHYSIOLOGICAL-CLINICAL,ventilation Radiological:RESOURCE-USE,changes:PHYSIOLOGICAL-CLINICAL,,
441,Duration of hospitalization Clinical,Duration of hospitalization Clinical:RESOURCE-USE,,,,,
442,The time from,,,,,,
443,Duration of severe,Duration of severe:PHYSIOLOGICAL-CLINICAL,,,,,
444,disappearance rate of,,,,,,
445,disappearance rate of COVID-19,disappearance:LIFE-IMPACT,,,,,
446,1. Proportion of subjects with,1. Proportion:PHYSIOLOGICAL-CLINICAL,,,,,
447,nan,,,,,,
448,virological clearance overtime during the study period clinical follow-up (body,the study period:LIFE-IMPACT,clinical:PHYSIOLOGICAL-CLINICAL,follow-up:LIFE-IMPACT,,,
449,nan,,,,,,
450,nan,,,,,,
451,time,,,,,,
452,nan,,,,,,
453,nan,,,,,,
454,Heart Failure Pulmonary Edema Allergic,,,,,,
455,Intensive Care Unit Admission,,,,,,
456,Absolute change in serum troponin from admission Discharge Rate Intubation Rate,Absolute:PHYSIOLOGICAL-CLINICAL,serum:PHYSIOLOGICAL-CLINICAL,troponin from admission Discharge:RESOURCE-USE,Rate:PHYSIOLOGICAL-CLINICAL,Intubation:RESOURCE-USE,Rate:PHYSIOLOGICAL-CLINICAL
457,change,change:LIFE-IMPACT,,,,,
458,Intensive Care Unit,,,,,,
459,nan,,,,,,
460,Requirement for non-invasive or mechanical ventilation Length of hospital stay in days Estimated PaO2/FiO2,Estimated:PHYSIOLOGICAL-CLINICAL,,,,,
461,Decrease,,,,,,
462,All cause,,,,,,
463,Overall,,,,,,
464,Response of,,,,,,
465,Patients achieving,,,,,,
466,Time to clinical improvement Clinical status Mean change in clinical status from,change:LIFE-IMPACT,in:PHYSIOLOGICAL-CLINICAL,clinical status:PHYSIOLOGICAL-CLINICAL,from:PHYSIOLOGICAL-CLINICAL,,
467,Rate of,,,,,,
468,composite of invasive mechanical,,,,,,
469,Hospital-free days at 28,Hospital-free days at 28:RESOURCE-USE,,,,,
470,Necessity of,,,,,,
471,Time to,,,,,,
472,Rate of housemate,of:PHYSIOLOGICAL-CLINICAL,,,,,
473,"all-location, all-cause mortality assessed on day 15 all-location, all-cause mortality assessed on day 29",,,,,,
474,Viral load Viral load Mortality Adverse events Positive SARS-CoV-2 test - nasal swab,,,,,,
475,Days of stay in the ICU,Days of:PHYSIOLOGICAL-CLINICAL,,,,,
476,Days on invasive mechanical ventilation,on:PHYSIOLOGICAL-CLINICAL,,,,,
477,Change in Respiratory Rate Change in Heart Rate Change in Blood Pressure,,,,,,
478,SAE Serious ADR,,,,,,
479,Hospital length,,,,,,
480,Lengh of,,,,,,
481,Time to improvement in oxygenation Mean change in oxygenation Number of,,,,,,
482,Changes of CD3 Changes of CD3 Changes of CD3 Changes of,,,,,,
483,Viral load Change in Clinical Condition,in:PHYSIOLOGICAL-CLINICAL,,,,,
484,Pulmonary Function Analysis,,,,,,
485,nan,,,,,,
486,Incidence,,,,,,
487,Physical statues of patient,,,,,,
488,Primary safety endpoint: major adverse cardiac events,,,,,,
489,Ventilator-free days,,,,,,
490,SARS-CoV-2,,,,,,
491,nan,,,,,,
492,Anti-SARS-CoV-2 titers Anti-SARS-CoV-2 titers,titers:LIFE-IMPACT,,,,,
493,nan,,,,,,
494,C-reactive proteins Lymphocyte,C-reactive:PHYSIOLOGICAL-CLINICAL,,,,,
495,Change from baseline Weight at,Change from:LIFE-IMPACT,,,,,
496,Number of,,,,,,
497,Type of respiratory support Duration,respiratory:PHYSIOLOGICAL-CLINICAL,,,,,
498,PCR levels Lactate clearance,,,,,,
499,Change from baseline to Day 5 in,,,,,,
500,30-day-survival vasopressor,,,,,,
501,Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.,assessed:PHYSIOLOGICAL-CLINICAL,,,,,
502,time to extubation length of intensive care unit,of intensive:PHYSIOLOGICAL-CLINICAL,,,,,
503,"Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs) Clinical status as assessed","Adverse Reactions (ARs), SAEs,:ADVERSE-EFFECTS",ARs:PHYSIOLOGICAL-CLINICAL,(SARs):PHYSIOLOGICAL-CLINICAL,Clinical:PHYSIOLOGICAL-CLINICAL,status as:PHYSIOLOGICAL-CLINICAL,
504,Evaluation of the clinical status All-cause mortality Mechanical ventilation duration Sequential Organ,mortality:MORTALITY,Mechanical:PHYSIOLOGICAL-CLINICAL,ventilation:RESOURCE-USE,,,
505,Number of patients with severe disease as,severe:PHYSIOLOGICAL-CLINICAL,,,,,
506,All cause mortality Systemic inflammation,,,,,,
507,"Time to Clinical Improvement (TTCI), Defined",,,,,,
508,nan,,,,,,
509,Lung injury score Oxygenation index In-hospital mortality,In-hospital:RESOURCE-USE,,,,,
510,ICU free days Hospital length of stay,of stay:RESOURCE-USE,,,,,
511,nan,,,,,,
512,need of admission in intensive care unit death rate of adverse events,,,,,,
513,All-cause,,,,,,
514,Time to SARS-CoV-2,to SARS-CoV-2:PHYSIOLOGICAL-CLINICAL,,,,,
515,Time,,,,,,
516,Efficacy of PP (Prone Positioning),(Prone Positioning):PHYSIOLOGICAL-CLINICAL,,,,,
517,Death Clinical status Mechanical venhtilation Hospitalization Time from treatment initiation to death Time to Negativization COVID 19 Fever,,,,,,
518,reduction of C-reactive protein or CRP Reduction of mechanical ventilation,,,,,,
519,The percentage of,,,,,,
520,30 days,,,,,,
521,Respiratory rate Heart rate Blood pressure,,,,,,
522,Occurrence and duration,,,,,,
523,Mortality rate at D30 Time,,,,,,
524,The differences in oxygen intake,oxygen:PHYSIOLOGICAL-CLINICAL,,,,,
525,Number of death,,,,,,
526,Ordinal scale in,,,,,,
527,Phase 2: The time to,,,,,,
528,Absolute mortality on days,,,,,,
529,Composite outcome:composite,,,,,,
530,nan,,,,,,
531,Treatment,,,,,,
532,WHO progression scale,,,,,,
533,Number,,,,,,
534,WHO progression,,,,,,
535,Categorization of hospitalization,,,,,,
536,All-cause mortality rate (main study),All-cause mortality rate:MORTALITY,,,,,
537,nan,,,,,,
538,Measure,,,,,,
539,Clinical cure rate,rate:PHYSIOLOGICAL-CLINICAL,,,,,
540,30-day mortality,,,,,,
541,Number of participants,,,,,,
542,Number of,,,,,,
543,All-cause mortality Incidence,All-cause:PHYSIOLOGICAL-CLINICAL,,,,,
544,Oxygenation Mechanical Ventilation Hospitalization,,,,,,
545,Time to category,,,,,,
546,Time of clinical recovery of fever Time of clinical recovery,recovery:PHYSIOLOGICAL-CLINICAL,of fever:PHYSIOLOGICAL-CLINICAL,Time of:PHYSIOLOGICAL-CLINICAL,clinical recovery:PHYSIOLOGICAL-CLINICAL,,
547,Duration of hospitalization Duration of mechanical ventilation Time,of:PHYSIOLOGICAL-CLINICAL,mechanical:PHYSIOLOGICAL-CLINICAL,ventilation:RESOURCE-USE,,,
548,Cardiac arrest Transfer to,,,,,,
549,Clinical,,,,,,
550,LDH level,,,,,,
551,Safety of,,,,,,
552,The proportion,,,,,,
553,Time to clinical recovery,Time to clinical recovery:PHYSIOLOGICAL-CLINICAL,,,,,
554,nan,,,,,,
555,Difference,,,,,,
556,nan,,,,,,
557,Number of days on supplemental,,,,,,
558,nan,,,,,,
559,Rates of death during,,,,,,
560,Phase 2: Change in the 8-point,,,,,,
561,Change in,,,,,,
562,Time from randomization,,,,,,
563,In-hospital mortality All-cause mortality,,,,,,
564,Montgomery √Ösberg,,,,,,
565,Incidence of GI adverse events Cardiac Toxicity,,,,,,
566,The number of,,,,,,
567,Rate of mortality within 28-days Size of lesion area,of:PHYSIOLOGICAL-CLINICAL,,,,,
568,Lung lesion Immune function Time of SARS-CoV-2 clearance Blood test,Immune function:PHYSIOLOGICAL-CLINICAL,,,,,
569,Days of respirator,,,,,,
570,nan,,,,,,
571,Impact of 300ml convP,,,,,,
572,Inpatient hospitalizations required,,,,,,
573,nan,,,,,,
574,Assessment of,,,,,,
575,Number of days,,,,,,
576,Symptom questionnaire Fever assessment Vital Signs - Body Temperature Discharge Recovery,Symptom questionnaire Fever assessment:PHYSIOLOGICAL-CLINICAL,,,,,
577,Adverse events,,,,,,
578,nan,,,,,,
579,Survival,,,,,,
580,clinical deterioration,clinical:PHYSIOLOGICAL-CLINICAL,,,,,
581,Number,,,,,,
582,The,,,,,,
583,Days,,,,,,
584,Duration,,,,,,
585,Mortality SpO2,,,,,,
586,Illness severity Number of patients with clinical improvement,Illness severity Number:PHYSIOLOGICAL-CLINICAL,,,,,
587,Decrease renal injury,,,,,,
588,Safety & Tolerability: incidence,,,,,,
589,Length of time participant spends in the,,,,,,
590,Time to reach an afebrile,,,,,,
591,Undetectable COVID PCR at day,,,,,,
592,Length of time tolerating prone,,,,,,
593,Time to,,,,,,
594,World Health Organisation(WHO) progression scale ‚â§5,,,,,,
595,Oxygen requirement of the patient Oxygen,patient:PHYSIOLOGICAL-CLINICAL,,,,,
596,Death Mechanical ventilation Intensive care unit,care:LIFE-IMPACT,,,,,
597,Overall survival Overall survival Cumulative incidence,Cumulative:PHYSIOLOGICAL-CLINICAL,,,,,
598,Early improvement: OMS progression scale <=,,,,,,
599,Evolution,,,,,,
600,Saturation of Oxygen in the blood,Saturation of Oxygen in:PHYSIOLOGICAL-CLINICAL,,,,,
601,nan,,,,,,
602,Clinic at hospitalization,Clinic at hospitalization:RESOURCE-USE,,,,,
603,Increase in oxygen saturation PaO2/FiO2 >300mmHg increase Reduction of IL-6,oxygen:PHYSIOLOGICAL-CLINICAL,,,,,
604,Incidence of,,,,,,
605,nan,,,,,,
606,Time to clinical,,,,,,
607,Proportion of patients who avoided,,,,,,
608,Proportion (%) of,,,,,,
609,Clinical outcome Hospital stay,,,,,,
610,Myocardial infarction Congestive cardiac failure,cardiac failure:PHYSIOLOGICAL-CLINICAL,,,,,
611,Mortality rates Number of defined daily dose,,,,,,
612,OMS progression scale ‚â§5,OMS progression scale ‚â§5:PHYSIOLOGICAL-CLINICAL,,,,,
613,Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators Comparison of change of lung involvement measurements in enrolled subjects towards historical,baseline total:PHYSIOLOGICAL-CLINICAL,,,,,
614,Clinical improvement by WHO,WHO:LIFE-IMPACT,,,,,
615,nan,,,,,,
616,All-cause mortality (intention to treat) Ventilator-free days (VFD) All-cause mortality with per protocol analysis,(intention to:LIFE-IMPACT,Ventilator-free days:RESOURCE-USE,All-cause mortality:MORTALITY,,,
617,Arterial thrombosis,,,,,,
618,Duration of,,,,,,
619,nan,,,,,,
620,Fever,,,,,,
621,Changes,,,,,,
622,Proportion,,,,,,
623,90,,,,,,
624,nan,,,,,,
625,Clinical,,,,,,
626,Number of death of,,,,,,
627,Change in estimated PaO2/FiO2 Number,,,,,,
628,Ventilator-free days,,,,,,
629,Mortality rate Number,,,,,,
630,Time to improvement of 2,Time to improvement of:PHYSIOLOGICAL-CLINICAL,,,,,
631,Overall survival Reduction in proportion of patients who require ventilation Reduction in length of Critical Care stay Reduction in,Overall survival Reduction in:MORTALITY,,,,,
632,Proportion of,,,,,,
633,All-cause-mortality Acute-inflammation-free,,,,,,
634,nan,,,,,,
635,"proportion of ""persistent responders""",,,,,,
636,WHO progression,,,,,,
637,Time fever resolution,resolution:PHYSIOLOGICAL-CLINICAL,,,,,
638,1st secondary,,,,,,
639,All-Cause Death Length of,,,,,,
640,Comfort with the interfaces,the interfaces:PHYSIOLOGICAL-CLINICAL,,,,,
641,Changes in,,,,,,
642,Changes in compound,,,,,,
643,Symptom Resolution: Fever Symptom,,,,,,
644,nan,,,,,,
645,Hospital re-admission Emergency Department visit Urgent Care,,,,,,
646,ICU mortality,,,,,,
647,"Immune biomarkers,",,,,,,
648,"Improving of PSQI, Improving of","PSQI,:PHYSIOLOGICAL-CLINICAL",,,,,
649,"SOFA, Serum",,,,,,
650,Rate of progression to severe,,,,,,
651,Self-Rating Anxiety Scale,Anxiety:LIFE-IMPACT,,,,,
652,"novel coronavirus nucleic acid clearance rate,",nucleic acid:PHYSIOLOGICAL-CLINICAL,,,,,
653,Clinical Severity Oxygenation: Mechanical,Clinical Severity:PHYSIOLOGICAL-CLINICAL,,,,,
654,1 - Percent of patients alive,Percent:PHYSIOLOGICAL-CLINICAL,,,,,
655,Receipt of,,,,,,
656,Duration of,Duration:RESOURCE-USE,,,,,
657,nan,,,,,,
658,nan,,,,,,
659,"DLco%, 6MWT,","DLco%,:PHYSIOLOGICAL-CLINICAL",,,,,
660,Pharmacokinetics: AUCinf ÔºåAUC0-t ÔºåAUC0-tauÔºåCmaxÔºåTmaxÔºåt1/2ÔºåCLÔºåVzÔºåMRTinfÔºåRac(AUC)ÔºåRac(Cmax),,,,,,
661,nan,,,,,,
662,- to study,- to:PHYSIOLOGICAL-CLINICAL,,,,,
663,Severe respiratory failure,,,,,,
664,‚Ä¢ Change in NEWS,,,,,,
665,1. Log transformed,,,,,,
666,1. ingresso in Terapia,,,,,,
667,-,,,,,,
668,-,,,,,,
669,1),,,,,,
670,Level of frailty,Level of frailty:PHYSIOLOGICAL-CLINICAL,,,,,
671,Side effects,Side effects:ADVERSE-EFFECTS,,,,,
672,-Time since,-Time since:PHYSIOLOGICAL-CLINICAL,,,,,
673,‚Ä¢ Comparison of the,‚Ä¢ Comparison of the:PHYSIOLOGICAL-CLINICAL,,,,,
674,Achievement of free,Achievement of:LIFE-IMPACT,,,,,
675,Number of days,Number of:PHYSIOLOGICAL-CLINICAL,,,,,
676,"WHO 7-point outcome scale (clinician assessed): Not hospitalized, no limitations",scale (clinician assessed)::PHYSIOLOGICAL-CLINICAL,"hospitalized, no limitations:PHYSIOLOGICAL-CLINICAL",,,,
677,"Intubation rate Time to intubation Time to death (mortality), obtained","Time to intubation Time to death (mortality), obtained:MORTALITY",,,,,
678,Duration of hospital stay (hours) Time to first receiving ventilation,hospital stay (hours) Time:RESOURCE-USE,first receiving ventilation:LIFE-IMPACT,,,,
679,"Recovery time, Virus nucleic acid negative time and rate, The",Virus nucleic acid:PHYSIOLOGICAL-CLINICAL,"time and rate, The:PHYSIOLOGICAL-CLINICAL",,,,
680,novel coronavirus nucleic acid detection,novel:LIFE-IMPACT,acid detection:PHYSIOLOGICAL-CLINICAL,,,,
681,Severity,Severity:PHYSIOLOGICAL-CLINICAL,,,,,
682,28-day mortality Need for ICU admission Length of ICU,Need for ICU:RESOURCE-USE,Length of ICU:RESOURCE-USE,,,,
683,Time to,,,,,,
684,toxicity,,,,,,
685,Ventilator-free,,,,,,
686,mortality Duration of mechanical ventilation Duration of oxygen,,,,,,
687,The major secondary,,,,,,
688,Adverse reactions,,,,,,
689,- Sociodemographic,,,,,,
690,all-cause mortality at D28,all-cause mortality at:MORTALITY,,,,,
691,- To asses in,- To asses:PHYSIOLOGICAL-CLINICAL,,,,,
692,‚Ä¢ Number of,‚Ä¢ Number:PHYSIOLOGICAL-CLINICAL,,,,,
693,Number of,,,,,,
694,Time to clinical,,,,,,
695,"The cycle threshold for SARS-CoV-2 PCR,",SARS-CoV-2:PHYSIOLOGICAL-CLINICAL,,,,,
696,-time to,,,,,,
697,1. Phase 2 and,,,,,,
698,Secondary end,,,,,,
699,nan,,,,,,
700,1.,,,,,,
701,overall survival through,overall:PHYSIOLOGICAL-CLINICAL,,,,,
702,nan,,,,,,
703,time to recovery,,,,,,
704,1) the rate of positive-to-negative conversion of,,,,,,
705,latency to pyrexia relief,,,,,,
706,nan,,,,,,
707,nan,,,,,,
708,nan,,,,,,
709,nan,,,,,,
710,Exercise,,,,,,
711,rate of hospital,,,,,,
712,improvement of clinical symptoms laboratory,,,,,,
713,total lymphocyte count subpopulation,total:PHYSIOLOGICAL-CLINICAL,count:PHYSIOLOGICAL-CLINICAL,,,,
714,Rate of mortality within 28-days Sequential organ failure assessment Side effects in,within 28-days Sequential organ failure:PHYSIOLOGICAL-CLINICAL,,,,,
715,P/F ratio over time Sequential organ failure assessment score(SOFA score) over time Pulmonary Severity Index (PSI) Image examination of chest over time,Sequential organ failure assessment:PHYSIOLOGICAL-CLINICAL,,,,,
716,Survival at 28 days Survival at 90 days SARS-free days at 28 days SARS -free days at 90 days Renal Replacement Therapy Liver Failure Mechanical Support of Circulation,28 days:RESOURCE-USE,,,,,
717,nan,,,,,,
718,Self-rating depression scale,Self-rating depression scale:LIFE-IMPACT,,,,,
